The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) who purchased shares between February 2, 2021 and June 10, 2021. The action, which was filed in the United States District Court for the Eastern District of Pennsylvania, alleges that the Company violated federal securities laws.
In particular, the Ocugen lawsuit alleges that (i) the information submitted to the U.S. Food and Drug Administration (“FDA”) was insufficient to support an Emergency Use Authorization (“EUA”), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Ocugen’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Shareholders have until August 17, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >